

RSV VACCINES FOR THE WORLD

14-16 October 2013, Tiara Park Atlantico Hotel, Porto, Portugal

FINAL ORAL PROGRAMME & POSTER PROGRAMME RSVVW 2013

SCIENTIFIC ADVISORY PANEL

Greg Glenn (*Novavax Inc., Rockville, Maryland, USA*)

Deborah Higgins (*PATH, Seattle, Washington, USA*)

James Crowe (*Vanderbilt University, Nashville, Tennessee, USA*)

Barney Graham (*NIH, Bethesda, Maryland, USA*)

Ruth Karron (*Johns Hopkins University, Baltimore, Maryland, USA*)

Philip Dormitzer (*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

Trudy Morrison (*University of Massachusetts, Worcester, Massachusetts, USA*)

Alexis Kalergis (*Pontificia Universidad Catolica de Chile/University of Nantes, France*)

Sylvain Fleury (*Mymetics Corporation, Epalinges, Switzerland*)

Ali Fattom (*NanoBio Corporation, Ann Arbor, Michigan, USA*)

Sylvia van den Hurk (*VIDO, University of Saskatchewan, Canada*)

Kees Leenhouts (*Mucosis, Groningen, The Netherlands*)

Rob Lambkin-Williams (*Retroscreen Virology Ltd, London, UK*)

Peter Openshaw (*Imperial College, London, UK*)

Judy Beeler (*CBER/FDA, Bethesda, Maryland, USA*)

Peter F. Wright (*Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA*)

Edward E. Walsh (*Rochester General Hospital, Rochester, New York, USA*)



Janet Englund (*Seattle Children's Hospital, Seattle, Washington, USA*)

Peter Collins (*NIAID/NIH, Bethesda, Maryland, USA*)

Jean-Francois Toussaint (*GSK Vaccines, Rixensart, Belgium*)

James Nokes (*KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK*)

Steven Varga (*University of Iowa, Iowa City, Iowa, USA*)



07.30 onwards

Registration

SESSION 1: OPENING PLENARY SESSION

Moderator: Gregory Glenn (*Novavax Inc., Rockville, Maryland, USA*)

09.00-09.10

RSVVW 2013 Conference Welcome & Introduction

Gregory Glenn (*Novavax Inc., Rockville, Maryland, USA*)
and Deborah Higgins (*PATH, Seattle, Washington, USA*)

09.10-09.40

'RSV Vaccines: The Road Ahead'

Ruth A. Karron (*The Johns Hopkins University, Baltimore, Maryland, USA*)

09.40-09.50

'Gates Foundation strategy for RSV'

Keith Klugman (*Gates Foundation, Seattle, Washington, USA*)

09.50-10.20

'Immunogenicity of RSV subunit vaccine candidates: An historical perspective'

Jean-Francois X. Toussaint (*GSK Biologicals, Rixensart, Belgium*)

10.20-10.50

'RSV vaccines: An unhappy past, but a hopeful future?'

Rob Lambkin-Williams (*Retroscreen Virology Ltd, London, UK*)

10.50-11.20

Coffee Break & Poster Set-Up

SESSION 2: RSV VACCINES IN CLINICAL DEVELOPMENT: SAFETY, IMMUNOGENICITY AND PATH FORWARD

Moderator: Deborah Higgins (*PATH, Seattle, Washington, USA*)

11.20-11.45

'Clinical experience with live-attenuated RSV vaccines'

Peter Collins (*NIAID/NIH, Bethesda, Maryland, USA*)

11.45-12.10

'Lessons for RSV from influenza and polio- diseases for which there are options of live, mucosally delivered and inactivated vaccine approaches'

Peter Wright
(*Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA*)

12.10-12.35

'Clinical experience with the RSV F nanoparticle vaccine'

Gregory Glenn (*Novavax Inc, Rockville, Maryland, USA*)

12.35-13.00

'A novel genetic vaccine to prevent RSV infection'

Elisa Scarselli (*Okairos Srl, Rome, Italy*)

13.00-14.00

Lunch Break & Posters

SESSION 3: RSV ANTIGENS

Moderator: Rob Lambkin-Williams (*Retroscreen Virology Ltd, London, UK*)

14.00-14.25

'Atomic structure of pre- and post-fusion RSV F'

Jason S. McLellan (*NIAID/NIH, Bethesda, Maryland, USA*)

14.25-14.50

'Structural vaccinology: is a pre-fusion RSV F antigen superior to post-fusion F'

Kurt A. Swanson, Ethan C. Settembre, Christine A. Shaw, Philip R. Dormitzer
and Andrea Carfi (*Novartis Vaccines, Cambridge, Massachusetts, USA*)

14.50-15.15

'Immunogenicity of a structure-based computationally designed RSV fusion protein subunit vaccine'

James Crowe (*Vanderbilt University, Nashville, Tennessee, USA*)

15.15-15.35

'A novel RSV F antigen designed to adopt PreF conformation: Immunogenicity, efficacy and safely in rodent models of RSV infection'

Ann-Muriel Steff, Jean-Francois Toussaint, Normans Blais and Denis Martin
(*GlaxoSmithKline Vaccines, Laval, Canada*)

15.35-15.55

'Options for using pre-fusion RSV F as a vaccine antigen'

Barney S. Graham (*NIH, Bethesda, Maryland, USA*)

15.55-16.15

Tea Break & Posters

SESSION 4: CLINICAL STRATEGIES TO ADDRESS THE BURDEN OF RSV DISEASE – PART I

Moderator: Pedro A. Piedra (*Baylor College of Medicine, Houston, Texas, USA*)

16.15-16.40

'Prevention of RSV in infants: Maternal immunization as a potential strategy'

Janet Englund (*Seattle Children's Hospital, Seattle, Washington, USA*)

16.40-17.05

'Maternal immunization for RSV - The promise and the challenge'

Deborah Higgins (*PATH, Seattle, Washington, USA*)

17.05-17.30

'Defining the duration of protective maternal RSV antibodies in infants'

James Nokes (*KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK*)

17.30-17.50

'Ethical, Social and cultural considerations in planning and conducting maternal immunization trials for RSV vaccines'

Billie-Jo Hardy (*University Health Network, Toronto, Ontario, Canada*)

17.50-18.10

'Transfer and decay of Respiratory Syncytial Virus antibody levels in mother-infant pairs in Bangladesh'

Helen Y. Chu, Mark C. Steinhoff, Gretchen Langdon, K. Zaman, Eliza Roy,
Mary Ann Formica, Edward Walsh and Janet A. Englund
(*University of Washington, Seattle, Washington, USA*)

18.10-18.30

'Long-term airway morbidity: A previously unrecognized health benefit of future RSV vaccines'

Louis Bont, Maarten O. Blanken, Maroeska M. Rovers, Jorine M. Molenaar,
Pauline L. Winkler-Seinstra, Adam Meijer and Jan L.L. Kimpen
(*University Medical Center Utrecht, Utrecht, The Netherlands*)

18.30

RSVVW 2013 Welcome & Poster Session

* This final programme is correct at the time of printing. However the organisers reserve the right to make any alterations that may be required in the interests and integrity of the final programme.

**SESSION 5:
CLINICAL STRATEGIES TO ADDRESS THE BURDEN
OF RSV DISEASE – PART II**

Moderator: Ruth Karron (*Johns Hopkins University, Baltimore, Maryland, USA*)

08.30-09.00

'Beyond the young infant: Disease burden and strategies for prevention'

Pedro A. Piedra (*Baylor College of Medicine, Houston, Texas, USA*)

09.00-09.30

'Disease and economic burden of RSV in infants in low- and middle-income countries'

Erin Sparrow (*WHO, Geneva, Switzerland*)

09.30-10.00

'Is vaccination feasible for older and high-risk adults?'

Edward Walsh (*Rochester General Hospital, Rochester, New York, USA*)

10.00-10.20

'Safety and immunogenicity of the RSV F nano particle vaccine in the elderly'

Louis Fries (*Novavax Inc., Rockville, Maryland, USA*)

10.25-10.40

'Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age'

Teun Guichelaar, Jeroen Hoeboer, Myra Widjoatmodjo, Sylvia Reemers, Cecile van Els, Rob Otten, Yvonne van Remmerden, Jolande Boes and Willem Luytjes (*RIVM, Bilthoven, The Netherlands*)

10.40-11.00

Coffee Break & Posters

**SESSION 6:
VACCINE APPROACHES:
ADDRESSING THE PATHOPHYSIOLOGY OF RSV**

Moderator: Philip Dormitzer

(*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

11.00-11.25

'The Novartis Dual RSV Vaccine Program'

Philip Dormitzer (*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

11.25-11.50

'Molecular and immunological basis for the induction of RSV F antigenic site II Palivizumab-like high affinity neutralizing antibodies with a recombinant nanoparticle RSV F vaccine candidate'

Gale Smith (*Novavax Inc, Rockville, Maryland, USA*)

11.50-12.15

'The RSV G protein and pathogenesis, treatment and prevention of disease'

Larry J. Anderson, S.Boyoglu-Barnum, T. Chirkova, K.A. Gaston, S.O. Todd, T.R. Barnum, L.M. Haynes, R.A. Tripp, A. Oomens and M.L. Moore (*Emory University, Atlanta, Georgia, USA*)

12.15-12.40

'Intramuscular administration of adenovirus vectors expressing RSV-F are highly immunogenic and protective in rodent models'

Lies Bogaert (*Cruceell, Leiden, The Netherlands*)

12.40-13.00

'A BCG-based vaccine induces protective immunity and prevents airway and CNS damage caused by RSV'

Alexis Kalergis (*Potificia Universidad Catolica de Chile, and INSERM U1064, University of Nantes, France*)

13.00-14.00

Lunch Break & Posters

**SESSION 7:
UNDERSTANDING RSV RELATED IMMUNE RESPONSES**

Moderator: Peter J.M. Openshaw (*Imperial College, London, UK*)

14.00-14.25

'Regulation of T cell activation in vaccine-augmented disease'

Peter J.M. Openshaw (*Imperial College, London, UK*)

14.25-14.50

'CD8 T cell memory to RSV: Can you have too much of a good thing?'

Steven M. Varga (*University of Iowa, Iowa City, Iowa, USA*)

14.50-15.10

'B cell responses following experimental RSV challenge in adult volunteers'

Christopher Chiu, Maximillian S. Habibi, Agnieszka Jozwik, Allan Paras, Spiros Makris and Peter J.M. Openshaw (*Imperial College, London, UK*)

15.10-15.30

'Enhanced disease associated with formalin-inactivated respiratory syncytial virus vaccination is not dependent upon eosinophils'

Cory J. Knudson, Stacey M. Hartwig, David K. Meyerholz and Steven M. Varga (*University of Iowa, Iowa City, Iowa, USA*)

15.30-15.50

Tea Break & Posters

**SESSION 8:
RSV ANIMAL MODELS: ON THE ROAD TO THE CLINIC**

Moderator: Marina Boukhvlava (*Sigmovir Biosystems Inc., Rockville, Maryland, USA*)

15.50-16.10

'The cotton rat *S. hispidus* model of RSV disease and its prevention'

Marina Boukhvlava (*Sigmovir Biosystems Inc., Rockville, Maryland, USA*)

16.10-16.30

'Baboon model for RSV'

Robert Welliver (*University of Oklahoma, Oklahoma, USA*)

16.30-16.50

'The cotton rat model for maternal immunization'

Max Ciarlet (*Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA*)

16.50-17.00

Short Break

**SESSION 9:
EXTRA SPECIAL SESSION**

Assay Standardization, Reference Materials and Vaccine Resources

Moderator: Judy Beeler (*CBER/FDA, Bethesda, Maryland, USA*)

17.00-17.20

'RSV resources coordinated by NIAID'

Sonnie Kim Grossman (*NIAID, Bethesda, Maryland, USA*)

17.20-17.40

'In-vitro and in-vivo confirmation of respiratory syncytial virus (RSV) – specific serum neutralizing antibody titer for the prevention of RSV-related hospitalization'

Pedro A. Piedra, Letisha Aideyan, Annette Machado, Alan Jewell, Robert L. Atmar, Roy F. Chemaly, Vivian Luchsinger, Luis F. Avendano and Brian Gilbert (*Baylor College of Medicine, Houston, Texas, USA*)

17.40-18.00

'Respiratory virus reference human immunoglobulin for use in quantitative virus neutralization assays'

Judy Beeler, Lynne Crim, Susette Audet, Ariel Isser, Mei-Ying Yu, Jan Varada, Keith Peden and Haru Murata (*CBER/FDA, Bethesda, Maryland, USA*)

18.00-18.20

'Next assay standardization'

Man Chen (*NIAID/NIH, Bethesda, Maryland, USA*)

18.20-18.40

'Towards an international standard for antibody to RSV'

Othmar Engelhardt (*NIBSC/MHPRA, Potters Bar, Hertfordshire, UK*)

SESSION 10:

RSV VACCINES: NEW APPROACHES AT THE PRECLINICAL STAGE OF DEVELOPMENT – PART I

Moderator: Sylvia van Drunen Little-van den Hurk
(VIDO, University of Saskatchewan, Canada)

08.40-09.00

'Evaluation of a virosomal Respiratory Syncytial Virus vaccine adjuvanted with monophosphoryl lipid A in cotton rats'

Toon Stegmann and Sylvain Fleury (Mymetics Corporation, Epalinges, Switzerland)

09.00-09.20

'Assessment of virus-like particle vaccine candidates Respiratory Syncytial Virus'

Trudy Morrison, Madelyn R. Schmidt, Lori W. McGinnes, Sarah Kenward and Robert Woodland (University of Massachusetts, Worcester, Massachusetts, USA)

09.20-09.40

'Vaccination with the RSV fusion protein formulated with a novel combination adjuvant induces long-lasting protective immunity'

Sylvia van Drunen Little-van den Hurk, R. Garg, L. Latimer, R. Brownlie, V. Gerdtts and A. Potter (VIDO, University of Saskatchewan, Canada)

09.40-10.00

'A protective and safe intranasal RSV vaccine based on a recombinant prefusion form of the F protein bound to a bacterium-like particle carrier'

Bert Jan Haijema, Alan Rigter, Ivy Widjaja, Hanneke Versantvoort, Maarten van Roosmalen, Kees Leenhouts, Peter J.M. Rottier and Cornelis A.M. de Haan (Mucosis BV, Groningen, The Netherlands)

10.00-10.20

'A nanoemulsion-inactivated and adjuvanted whole virus RSV vaccine: Immunogenicity and protection in mice and cotton rats following intranasal or intramuscular administration'

Ali Fattom (NanoBio Corporation, Ann Arbor, Michigan, USA)

10.20-10.40 LATEBREAKER:

'Co-delivery of intranasal viral vaccines with retinyl palmitate corrects impaired mucosal IgA responses in vitamin A deficient hosts'

Julia L. Hurwitz et al.
(St. Jude Children's Research Hospital, Memphis, Tennessee, USA)

10.40-11.00

Coffee Break & Posters

SESSION 11:

RSV VACCINES: NEW APPROACHES AT THE PRECLINICAL STAGE OF DEVELOPMENT – PART II

Moderator: Ali Fattom (NanoBio Corporation, Ann Arbor, Michigan, USA)

11.00-11.20

'DepoVax™ formulated vaccine to RSV targets novel mechanism of action'

Marc Mansour, Marianne Stanford, Lisa MacDonald, Bert Schepens, Koen Sedeyn, Walter Fiers, Alecia MacKay, Valarmathy Kaliaperumal, Bithika Ray, Tara Quinton, Kendall Sharp, Rajkannan Rrajagopalan, Leeladhar Sammatwar and Xavier Saelens (Immunovaccine Inc., Halifax, Nova Scotia, Canada)

11.20-11.40

'Protective efficacy induced by a live, attenuated rBRSV vaccine and a subunit vaccine containing P, M2-1 and N-nanorings displaying epitopes of F and G, against BRSV in calves'

Krister Blodorn, S. Hagglund, J. Fix, C. Dubuquoy, B. Makabi-Panzu, M. Thom, J.L. Roque, E. Karlstam, J.Pringle, J.F. Eleouet, S. Riffault, G. Taylor and J.F. Valarcher (Swedish University of Agricultural Sciences, Uppsala, Sweden)

11.40-12.00

'She's a novel target for RSV vaccination'

Bert Schepens, Liesbeth Vande Ginste, Sarah De Baets, Koen Seydyen, Iebe Rossey, Pieter Bogaert, Brian Gilbert, Pedro A Piedra, Water Fiers and X. Saelens (Ghent University/VIB, Ghent, Belgium)

12.00-12.20

'Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization'

Cyril le Nouen, Linda G. Brock, Cindy Luongo, Thomas McCarty, Lijuan Yang, Eckard Wimmer, Steffen Mueller, Peter L. Collins, Ursula J. Buchholz and Joshua M. DiNapoli (NIAID/NIH, Bethesda, Maryland, USA)

12.20-12.40

'Respiratory Syncytial Virus with codon-deoptimized NS1 and NS2 genes is attenuated and immunogenic'

Jia Meng, Sujin Lee and Martin L. Moore (Emory University, Atlanta, Georgia, USA)

12.40-13.00

'Developing a recombinant adenovirus carrying F protein of RSV as a vaccine for preventing lower respiratory infections caused by RSV'

Yen-Hung Chow and Hsiao-Yun Shao
(National Health Research Institutes, Zhunan Town, Taiwan)

13.00-14.00

Lunch Break & Posters Breakdown

SESSION 12:

RSV PROTECTION USING NON-VACCINE APPROACHES & LATE BREAKER PRESENTATIONS

Moderator: Martin Friede (WHO, Geneva, Switzerland)

14.00-14.20

'Development of affordable immunoprophylaxis against RSV'

Martin Friede (WHO, Geneva, Switzerland)

14.20-14.40

'Development of ALX-0171, an inhaled Nanobody® for the treatment of respiratory syncytial virus infection in infants'

Erik Depla (Ablynx NV, Zwijnaarde, Belgium)

14.40-15.00

'Polyclonal human IVIG with standardized high-levels of RSV neutralizing antibodies: A summary of animal and human studies'

Ann R. Falsey, Edward E. Walsh and James J. Mond
(Rochester General Hospital, Rochester, New York, USA)

15.00-15.20

'Correlation of RSV neutralizing antibody with protection against RSV lower respiratory tract illness: Results from an RSV-IGIV prevention trial'

Eric Simoes et al. (University of Colorado, Aurora, Colorado, USA)

15.20-15.40

'Identification of respiratory syncytial virus A and B strains lacking most of the G protein ecto domain in immunocompromised patients hospitalized with severe acute respiratory illness in South Africa'

Marietjie Venter, Marthi A. Pretorius and Florette Treurnicht
(NHLS, Johannesburg, South Africa)

15.40-16.00

Tea Break

16.00-17.00

SESSION 13:

EXTRA SPECIAL PANEL DISCUSSION SESSION

'Defining clinical endpoints for efficacy trials in various target populations'

Moderator: Cheryl Keech (PATH, Seattle, Washington, USA)

Panelists:

Ruth A. Karron (The Johns Hopkins University, Baltimore, Maryland, USA)

James Nokes (KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK)

Edward E. Walsh (Rochester General Hospital, Rochester, New York, USA)

Janet Englund (Seattle Children's Hospital, Seattle, Washington, USA)

17.00

Closing Remarks & Departure

Poster 101

'Recombinant RSV strains with enhanced fusion activity exhibit relatively high viral load and pathogenicity in BALB/c mice'

Martin L. Moore et al. (Emory University, Atlanta, Georgia, USA)

Poster 102

'A role for TLR-environment interactions effected through T helper type 2 polarization in severe RSV bronchiolitis'

Fernando P. Polack et al. (Vanderbilt University, Nashville, Tennessee, USA)

Poster 103

'Targeting passive prophylaxis: Gender and breastfeeding determine susceptibility for severe respiratory syncytial virus (RSV) infection and protective efficacy of palivizumab in very low birth weight infants in a developing country'

Fernando P. Polack et al. (Vanderbilt University, Nashville, Tennessee, USA)

Poster 104

'Targeting vaccines against respiratory pathogens: Deaths in hospitalized infants in a developing country'

Fernando P. Polack et al. (Vanderbilt University, Nashville, Tennessee, USA)

Poster 105

'Targeting the RSV fusion receptor reduces viral replication and airway inflammation in mice'

Peter Mastrangelo et al. (University of Toronto, Toronto, Ontario, Canada)

Poster 106

'The RSV fusion protein formulated with a novel combination adjuvant induces protective immunity in lambs with maternal antibodies'

Ravendra Garg et al. (VIDO, University of Saskatchewan, Saskatoon, Canada)

Poster 107

'Nasal immunization of cotton rats with recombinant RSV lacking glycoprotein G induces long term protection against RSV challenge infection'

Jolande Boes et al. (Intravacc, Bilthoven, The Netherlands)

Poster 108

'Vaccine concept based on a respiratory syncytial virus with a genomic deficiency complemented in trans'

Otto de Boer (Intravacc, Bilthoven, The Netherlands)

Poster 109

'Automated quantitative image analysis of goblet cell hyperplasia in a mouse model of RSV infection'

Simone P. Zehntner et al. (Biospective Inc., Montreal, Quebec, Canada)

Poster 110

'Molecular and structural characterization of RSV F antigen designed to adopt pre-fusion conformation and comparison with F antigen in post-fusion conformation'

Normand Blais et al. (GlaxoSmithKline Vaccines, Laval, Quebec, Canada)

Poster 111

'Cellular and humoral immune responses to RSV exposure in health care workers'

Christopher Green et al. (University of Oxford, Oxford, UK)

Poster 112

'Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice'

Lia M. Haynes et al. (CDC, Atlanta, Georgia, USA)

Poster 113

'Immunogenicity, efficacy and safety of a respiratory syncytial virus recombinant F protein vaccine in cotton rats'

Ann-Muriel Steff et al. (GlaxoSmithKline Vaccines, Laval, Quebec, Canada)

Poster 114

'Proof of concept of the efficacy of a maternal RSV, recombinant F protein, vaccine for protection of offspring in the guinea pig model'

Ann-Muriel Steff et al. (GlaxoSmithKline Vaccines, Laval, Quebec, Canada)

Poster 115

'Differential RSV seasonal patterns in Florida, Puerto Rico and other US regions'

Marika Iwane et al. (CDC, Atlanta, Georgia, USA)

Poster 116

'Investigation of respiratory syncytial virus-associated deaths among children in four US states, 2004-2007'

Mila M. Prill et al. (CDC, Atlanta, Georgia, USA)

Poster 117

'RSV-vaccine candidates based on a modified vaccinia virus Ankara (MVA) platform technology for the prevention of diseases caused by respiratory syncytial virus'

Kathrin Kindsmueller and Sonia Leyrer (Emergent BioSolutions Inc., Rockville, Maryland, USA)

Poster 118

'Characterization of recombinant adeno-associated virus vectors expressing RSVF neutralizing antibodies'

Rebecca J. Loomis and Philip R. Johnson (Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA)

Poster 119

'Assessing promising practices and barriers for improving influenza vaccine coverage among employees in Pennsylvania health Care Facilities'

Sara Ferrick and O. Simwale (The Pennsylvania State University, Harrisburg, Pennsylvania, USA)

Poster 120

'Safety, reactogenicity and immunogenicity of a single intramuscular dose of two formulations of a candidate RSV vaccine in healthy adults aged 18-51 years: a phase I, single-blind, randomized comparative study'

Jean-Francois X. Toussaint et al. (GlaxoSmithKline Vaccines, Rixensart, Belgium)

Poster 121

'Immunogenicity, reactogenicity and safety of three formulations of a candidate RSV vaccine, each administered as a single intramuscular dose in healthy adults aged >65 years: a double-blind randomized study'

Edward Walsh et al. (University of Rochester, Rochester, New York, USA)

Poster 122

'A rationally designed woodchuck hepadnavirus VLP displaying RSV palivizumab epitope elicits RSV neutralizing antibody and protects mice from challenge'

David C. Whitacre et al. (VLP Biotech Inc., San Diego, California, USA)

Poster 123

'Co-immunization with VLP and DNA vaccines confers protection against RSV without pulmonary inflammatory disease'

Sang-Moo Kang et al. (Georgia State University, Atlanta, Georgia, USA)

Poster 124

'Differential outcomes of maternal antibodies in protection and disease'

Sang-Moo Kang et al. (Georgia State University, Atlanta, Georgia, USA)

Poster 125

'The burden of respiratory syncytial virus (RSV) infection in children in the United Kingdom'

Sylvia Taylor et al. (GlaxoSmithKline Vaccines, Wavre, Belgium)

Poster 126

'The burden of respiratory syncytial virus (RSV) infection in adults and the elderly in the United Kingdom'

Douglas Fleming et al. (Independent Consultant, Birmingham, UK)

Poster 127

'Molecular epidemiology of respiratory syncytial virus (RSV) in Fukushima, Japan, 2007-2012 and evaluation of clinical RSV strains using mouse infection model'

Koichi Hashimoto et al. (Fukushima Medical University, Fukushima, Japan)

Poster 128

'Burden of human respiratory syncytial virus (RSV) infection'

Ida Kolte et al. (Crucell Holland BV, Leiden, The Netherlands)

Poster 129

'Protection of cotton rats against human respiratory syncytial virus infection by mRNA-based vaccination without disease enhancement'

M. Fotin-Mleczek et al. (CureVac GmbH, Tübingen, Germany)

Poster 130

'A study of inactivated trivalent influenza vaccine among children in rural India 2009-2010: a possible platform for future RSV vaccine trials'

Wayne Sullender et al. (University of Colorado Denver, Denver, Colorado, USA)

Poster 131

'Impaired learning resulting from respiratory syncytial virus infection'

Sebastian A. Riquelme et al. (Pontificia Universidad Católica de Chile, Santiago, Chile)

Poster 132

'Contribution of FcI⁺ receptors to respiratory syncytial virus pathogens and the impairment of T cell activation by dendritic cells'

Roberto S. Gomez et al. (Pontificia Universidad Católica de Chile, Santiago, Chile)

Poster 133

'Immunization with a recombinant BCG strain confers protective Th1 immunity against the human metapneumovirus'

Susan M. Bueno et al. (Pontificia Universidad Católica de Chile, Santiago, Chile)

Poster 134

'The source of respiratory syncytial virus infection in infants: A household cohort study in rural Kenya'


Patrick K. Munywoki et al. (KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya)

FINAL CONFERENCE PROGRAMME · SPONSORS

The RSVVW 2013 Scientific Advisory Panel and the organizers would like to acknowledge the support of the following sponsors:

Mucosis
Vaccines that mimic nature

NOVAVAX



RETROSCREEN VIROLOGY
CONQUERING VIRAL DISEASE

pevion
V A C C I N E S
where efficacy meets safety

 **NOVARTIS**
VACCINES

 **MYMETICS**
Vaccines for Tomorrow

 **aldevron**

 **PATH**
A catalyst for global health

NanoBio[®]
Corporation

NatureGeneTherapy.com
Gene-based vaccine therapy

SANOFI PASTEUR 

inovio
PHARMACEUTICALS

 **Ablynx**

 **Crucell**


okairos
from genes to vaccines

IMV
Immunovaccine

 **ADMA**
BIOLOGICS, INC

 **vlp**
Biotech